LETS

*First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer, Adjuvant treatment of oestrogen-receptor-positive invasive early breast cancer in postmenopausal women, Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received standard adjuvant tamoxifen therapy for 5 years, Neo-adjuvant treatment in postmenopausal women with localized hormone-receptor-positive, human epidermal growth factor-2 negative breast cancer where chemotherapy is not suitable and surgery not yet indicated:* Adult: 2.5 mg daily.

Pre-menopausal women, very severe hepatic impairment.

Very severe renal impairment.Susceptibility to osteoporosis

Alopecia, anorexia, appetite increase, arthralgia, bone fracture, constipation, depression, diarrhoea, dizziness, dry skin, dyspepsia, fatigue, headache, hot flushes, hypercholesterolaemia, hypertension, increased sweating, musculoskeletal pain, nausea, osteoporosis, peripheral oedema, rash, vaginal bleeding, vomiting, weight changes, anxiety, arthritis, blurred vision, breast pain, cardiac events, cataract, cerebrovascular events, cough, dysaesthesia, dyspnea, leucopenia, memory impairment, mucosal dryness, palpitation, pruritus, pyrexia, stomatitis, tachycardia, thrombophlebitis, tumour, urinary frequency, urinary-tract infection, urticaria, hepatitis, toxic epidermal necrolysis. Rare Arterial thrombosis, pulmonary embolism